Muscular Dystrophies clinical trials at UCLA
3 in progress, 0 open to eligible people
AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Sorry, accepting new patients by invitation only
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Los Angeles, California and other locations
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Sorry, in progress, not accepting new patients
AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients
Los Angeles, California and other locations
AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Sorry, in progress, not accepting new patients
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Los Angeles, California and other locations
Our lead scientists for Muscular Dystrophies research studies include Perry B. Shieh, MD, PhD.
Last updated: